Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | March 06, 2013

The Radial Access Adoption Report Card

Over the past decade in the United States, there has been growing interest in transradial artery percutaneous access as a way to significantly reduce bleeding rates and access site complications. However, adoption in the United States has been slow compared to other parts of the world, partly due to lack of training in interventional programs until recently. In articles and sessions at various cardiology conferences, I have heard varying U.S. adoption rate percentages.  

One of the biggest advocates for expanding radial access is Sunil V. Rao, M.D., FACC, assistant professor of medicine at Duke University Medical Center and director of the cardiac cath lab at the Durham VA Medical Center, Durham, N.C. He asked the same question about U.S. radial access usage and found it accounted for 3 percent of cath lab access in his 2008 study[1] of the American College of Cardiology’s CathPCI Registry of the National Cardiovascular Data Registry (NCDR). The CathPCI Registry collects data from about 85 percent of the cardiac cath labs in the United States.

Since 2008, there has been a big push from radial evangelists such as Rao and others to spread the word about the benefits of radial access.  That message has been amplified in recent years in an era of reduced reimbursements and healthcare reform forcing hospitals to look for new ways to reduce costs, including reducing hospital length of stay and complications.

An updated NCDR snapshot of radial access between January 2010 and June 2011 was published in December 2012.  The study showed radial access usage rose to 8.3 percent[2], based on a review of 1.1 million patients undergoing diagnostic cardiac catheterization and 941,248 undergoing percutaneous coronary intervention (PCI). 

This growth rate combined with the introduction of radial training programs in recent years has some experts now predicting a 15 percent radial access usage rate by 2014. 

I wrote a column three years ago that asked why radial access is not more widely used if study after study shows it can slash complication rates, increase patient safety and reduce length of stay and nursing time?  The question I posed then still stands. Out of all the columns and articles ever written in DAIC, that column generated, by far, the most reader comments we ever received. DAIC’s most read website content also includes several transradial access stories in the top 20 articles for 2012. 

One major change that could spur radial’s increased usage would be recognition of its benefits by the Centers for Medicare and Medicaid Services (CMS) by offering higher reimbursements for radial over femoral access. From the level of evidence seen in studies, this increased cost would be offset downstream by greatly lowering the costs to treat complications. 

 

References: 

 

1. Sunil V. Rao, Fang-Shu Ou, Tracy Y. Wang, et al. “Trends in the Prevalence and Outcomes of Radial and Femoral Approaches to Percutaneous Coronary Intervention.” J Am Coll Cardiol Intv. 2008;1(4):379-386. doi:10.1016/j.jcin.2008.05.007.

2. Gregory J. Dehmer, Douglas Weaver, Matthew T. Roe, et al. “A Contemporary View of Diagnostic Cardiac Catheterization and Percutaneous Coronary Intervention in the United States A Report From the CathPCI Registry of the National Cardiovascular Data Registry, 2010 Through June 2011.” J Am Coll Cardiol. 2012;60(20):2017-2031. doi:10.1016/j.jacc.2012.08.966

Related Content

Bard, Lutonix 014 DCB, drug-coated balloon, six-month endpoint, FDA IDE trial
Technology | Drug-Eluting Balloons| September 26, 2016
C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE...
smartphones, hospital tranfers, heart attack patients, JACC study, South Korea
News | Mobile Devices| September 23, 2016
Smartphone communication among medical teams at different hospitals can significantly reduce the time it takes for...
Robert M. Califf, FDA commissioner, future of cardiovascular medicine, JACC column
News | Business| September 23, 2016
Technology advances coupled with increased use of social media and personal devices could offer new possibilities for...
Medtronic, In.Pact Admiral drug-coated balloon, trial data, VIVA
News | Drug-Eluting Balloons| September 22, 2016
New data presented at the Vascular Interventional Advances (VIVA) conference demonstrated the durability, consistency...
4Tech, TriCinch TTVR, transcather tricuspid valve repair device, first implant
News | Heart Valve Technology| September 22, 2016
4Tech Inc. announced that its TriCinch device has been used in the world’s first-ever successful transcatheter...
Transesophageal Echo, TEE. Interventional echocardiography, interventional echo, Philips, CX50

Transesophageal echo (TEE) has become an essential part of the new transcatheter structrual heart therapies, giving rise to a new sub-speciality of interventional echocardiography.  

Feature | Cath Lab Navigation Aids| September 21, 2016 | Dave Fornell
The rapid growth of transcatheter structural heart procedures and the need for increased use of echocardiography as a
Sponsored Content | Videos | Inventory Management| September 21, 2016
With bundled payments putting increased pressure on hospitals to manage supply costs while providing quality patient
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
Teleflex, AVA 2016 Congress, Association for Vascular Access
News | Vascular Access| September 20, 2016
September 20, 2016 — Teleflex Inc.
Edwards sapien, intermediate risk patients, CE mark
News | Heart Valve Technology| September 20, 2016
September 19, 2016 — Edwards Lifesciences received European CE mark to expand use of the Edwards Sapien 3 transcathet
Overlay Init